Tags

Type your tag names separated by a space and hit enter

The AcrySof Toric intraocular lens in subjects with cataracts and corneal astigmatism: a randomized, subject-masked, parallel-group, 1-year study.
Ophthalmology. 2010 Nov; 117(11):2104-11.O

Abstract

PURPOSE

To compare the AcrySof Toric intraocular lens (IOL) and an AcrySof spherical control IOL and to investigate rotational stability of the AcrySof Toric IOL (Alcon Laboratories, Inc., Fort Worth, TX) in subjects with cataracts and preexisting corneal astigmatism.

DESIGN

Randomized, subject-masked, parallel-group, multicenter, 1-year study.

PARTICIPANTS

We included 517 subjects (Toric IOL, n = 256; control IOL, n = 261).

METHODS

Unilateral implantation of an AcrySof Toric or AcrySof spherical control IOL (spherical powers, 12.00-25.00 diopters [D]; cylinder powers 1.50, 2.25, or 3.00 D for corneal astigmatism correction of 0.75 to < 1.50, ≥ 1.50 to <2.00, and ≥ 2.00 D with no upper limit, respectively). No limbal relaxing incisions were permitted.

MAIN OUTCOME MEASURES

Visual acuity outcomes, IOL position, patient-reported spectacle use, and safety.

RESULTS

One year postoperatively, best spectacle-corrected distance visual acuity of ≥ 20/20 was 77.7% (Toric IOL) versus 69.2% (control IOL). Uncorrected distance visual acuity of 20/20 or better was 40.7% (Toric IOL) versus 19.4% (control IOL; P<0.05). Mean absolute residual refractive cylinder was 0.59 D (Toric IOL) versus 1.22 D (control IOL; P<0.0001). Mean rotation was < 4° (range, 0°-20°) for the Toric IOL. Six-month spectacle freedom was 61.0% (Toric IOL) and 36.4% (control IOL; P < 0.0001). Complications in both groups were few and were as would be expected with cataract surgery.

CONCLUSIONS

Favorable efficacy, rotational stability, distance vision spectacle freedom, and safety results support the use of the AcrySof Toric IOL for patients with cataracts and corneal astigmatism.

FINANCIAL DISCLOSURE(S)

Proprietary or commercial disclosure may be found after the references.

Authors+Show Affiliations

Cincinnati Eye Institute, University of Cincinnati, Cincinnati, Ohio, USA. eholland@fuse.netNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20846724

Citation

Holland, Edward, et al. "The AcrySof Toric Intraocular Lens in Subjects With Cataracts and Corneal Astigmatism: a Randomized, Subject-masked, Parallel-group, 1-year Study." Ophthalmology, vol. 117, no. 11, 2010, pp. 2104-11.
Holland E, Lane S, Horn JD, et al. The AcrySof Toric intraocular lens in subjects with cataracts and corneal astigmatism: a randomized, subject-masked, parallel-group, 1-year study. Ophthalmology. 2010;117(11):2104-11.
Holland, E., Lane, S., Horn, J. D., Ernest, P., Arleo, R., & Miller, K. M. (2010). The AcrySof Toric intraocular lens in subjects with cataracts and corneal astigmatism: a randomized, subject-masked, parallel-group, 1-year study. Ophthalmology, 117(11), 2104-11. https://doi.org/10.1016/j.ophtha.2010.07.033
Holland E, et al. The AcrySof Toric Intraocular Lens in Subjects With Cataracts and Corneal Astigmatism: a Randomized, Subject-masked, Parallel-group, 1-year Study. Ophthalmology. 2010;117(11):2104-11. PubMed PMID: 20846724.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The AcrySof Toric intraocular lens in subjects with cataracts and corneal astigmatism: a randomized, subject-masked, parallel-group, 1-year study. AU - Holland,Edward, AU - Lane,Stephen, AU - Horn,Jeffrey D, AU - Ernest,Paul, AU - Arleo,Robert, AU - Miller,Kevin M, Y1 - 2010/09/16/ PY - 2009/09/15/received PY - 2010/07/19/revised PY - 2010/07/28/accepted PY - 2010/9/18/entrez PY - 2010/9/18/pubmed PY - 2010/11/4/medline SP - 2104 EP - 11 JF - Ophthalmology JO - Ophthalmology VL - 117 IS - 11 N2 - PURPOSE: To compare the AcrySof Toric intraocular lens (IOL) and an AcrySof spherical control IOL and to investigate rotational stability of the AcrySof Toric IOL (Alcon Laboratories, Inc., Fort Worth, TX) in subjects with cataracts and preexisting corneal astigmatism. DESIGN: Randomized, subject-masked, parallel-group, multicenter, 1-year study. PARTICIPANTS: We included 517 subjects (Toric IOL, n = 256; control IOL, n = 261). METHODS: Unilateral implantation of an AcrySof Toric or AcrySof spherical control IOL (spherical powers, 12.00-25.00 diopters [D]; cylinder powers 1.50, 2.25, or 3.00 D for corneal astigmatism correction of 0.75 to < 1.50, ≥ 1.50 to <2.00, and ≥ 2.00 D with no upper limit, respectively). No limbal relaxing incisions were permitted. MAIN OUTCOME MEASURES: Visual acuity outcomes, IOL position, patient-reported spectacle use, and safety. RESULTS: One year postoperatively, best spectacle-corrected distance visual acuity of ≥ 20/20 was 77.7% (Toric IOL) versus 69.2% (control IOL). Uncorrected distance visual acuity of 20/20 or better was 40.7% (Toric IOL) versus 19.4% (control IOL; P<0.05). Mean absolute residual refractive cylinder was 0.59 D (Toric IOL) versus 1.22 D (control IOL; P<0.0001). Mean rotation was < 4° (range, 0°-20°) for the Toric IOL. Six-month spectacle freedom was 61.0% (Toric IOL) and 36.4% (control IOL; P < 0.0001). Complications in both groups were few and were as would be expected with cataract surgery. CONCLUSIONS: Favorable efficacy, rotational stability, distance vision spectacle freedom, and safety results support the use of the AcrySof Toric IOL for patients with cataracts and corneal astigmatism. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references. SN - 1549-4713 UR - https://www.unboundmedicine.com/medline/citation/20846724/The_AcrySof_Toric_intraocular_lens_in_subjects_with_cataracts_and_corneal_astigmatism:_a_randomized_subject_masked_parallel_group_1_year_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0161-6420(10)00815-8 DB - PRIME DP - Unbound Medicine ER -